Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

OncoAlert and ecancer weekly round up for July 1- July 10, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 1- July 10, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and...

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng - National University of Singapore, Singapore )

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non...

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

$Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )$

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non...

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

Efficacy and safety of tisagenlecleucel in adult patients with relapsed...

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA

$Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )$

First results of a head-to-head trial of acalabrutinib versus ibrutinib in...

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Prof John Allan - Weill Cornell Medicine, New York, USA

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )

Interim results of a phase II study of blinatumomab plus ponatinib for...

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer